Company Expects 2026 Global Net Revenue of EUR 36M to EUR 40M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13 hours ago
0mins
The company said, "The Company continues to expect global net revenue for the full year 2026 to be in the range of EUR 36 million to EUR 40 million."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NYXH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NYXH
Wall Street analysts forecast NYXH stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.770
Low
5.82
Averages
10.41
High
13.00
Current: 1.770
Low
5.82
Averages
10.41
High
13.00
About NYXH
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nyxoah SA Reports 21% Revenue Growth in Q2 2026
- Significant Revenue Growth: Nyxoah SA reported preliminary revenue of approximately €7.7 million for Q2 2026, reflecting a 21% sequential increase over Q1 2026, indicating strong market performance and ongoing growth potential.
- Strong U.S. Market Performance: The company expects U.S. net revenue to be around €5.2 million, representing a 22% sequential growth from Q1 2026, demonstrating the effectiveness of its expansion strategy in the U.S. market and further solidifying its market position.
- Robust Financing Situation: Nyxoah secured $110 million in aggregate financing in Q2, enhancing its financial flexibility, with cash, cash equivalents, and financial assets expected to be approximately €97.8 million as of June 30, 2026, providing a solid foundation for future investments.
- Stable Annual Revenue Outlook: The company anticipates global net revenue for 2026 to be in the range of €36 million to €40 million, reflecting confidence in future market demand and a strategic plan for sustained growth.
See More
Nyxoah SA Voting Rights and Share Information Released
- Share Issuance: Nyxoah SA issued 146,531 new shares on June 30, 2026, increasing its total share capital to EUR 7,075,152.31, indicating a proactive approach to expanding its capital base.
- Total Voting Rights: The total number of voting rights currently stands at 100,072,815, all of which are ordinary shares, providing investors with transparent shareholder structure information that helps enhance market confidence.
- Unissued Subscription Rights: The company has 3,731,884 subscription rights that have not yet been issued, which presents potential opportunities for future financing and further expansion of shareholder equity.
- Convertible Bond Information: Nyxoah SA currently holds 225 convertible bonds with a nominal value of EUR 83,000 each, and if fully converted, would generate 12,618,243 new shares, further diluting the existing shareholders' equity.
See More
Nyxoah Receives Transparency Notifications from Major Shareholders
- Shareholder Notification: In accordance with Article 14 of the Law of May 2, 2007, Nyxoah SA received a transparency notification from Orin Hirchman, indicating that entities controlled by him held 14,534,880 voting rights as of June 10, 2026, representing 14.55% of total shares, highlighting his significant shareholder status in the company.
- Holding Structure Explanation: Hirchman controls these shares through AIGH Capital Management LLC, which manages two affiliated funds, AIGH Investment Partners, LP and WVP Emerging Manager Onshore Fund LLC, indicating his pivotal role in investment decisions that could influence the company's strategic direction.
- Resmed Inc. Notification: On the same day, Nyxoah also received a transparency notification from Resmed Inc., indicating a passive downward crossing to 1.95% voting rights as of June 10, 2026, reflecting a reduction in their stake that may affect market confidence in their holdings.
- Transparency Compliance: This notification complies with transparency regulations, ensuring a clear understanding of shareholder structure in the market, enhancing investor trust in corporate governance, and providing a transparent foundation for future capital operations.
See More
Nyxoah Invites Shareholders to Extraordinary Meeting on July 9, 2026
- Extraordinary Meeting Details: Nyxoah is set to hold its extraordinary shareholders' meeting on July 9, 2026, at 2:00 PM CET at its headquarters in Belgium, allowing shareholders to participate remotely via video conference, thereby enhancing shareholder engagement and interaction.
- Capital Authorization Renewal Proposal: The agenda includes a proposal from the board to renew the authorization for capital increases over the next five years, aimed at providing financial support for the company's long-term growth and enhancing capital flexibility.
- Voting and Participation Requirements: Shareholders must register by June 25, 2026, and notify the company of their intention to participate by July 3, ensuring compliance and increasing the effectiveness of voting, which promotes active shareholder involvement.
- Transparency and Data Protection: The company commits to adhering to its privacy policy while processing personal data during the shareholders' meeting, ensuring the security and transparency of shareholder information, which enhances trust in the company.
See More
Nyxoah Discloses Voting Rights and Share Information
- Share Issuance: Nyxoah SA issued 55,232,558 new shares in its underwritten public offering in the U.S., raising its total share capital to EUR 7,073,687, indicating active engagement in capital markets and financing capabilities.
- Total Voting Rights: As of June 10, 2026, Nyxoah has a total of 99,926,284 voting rights, all pertaining to ordinary shares, reflecting the company's transparency and compliance in shareholder structure.
- Convertible Bonds Information: The company currently has 225 convertible bonds with a nominal value of EUR 83,000 each, which could potentially convert into 12,618,243 voting rights, showcasing opportunities for capital expansion.
- Subscription Rights Status: As of May 31, 2026, Nyxoah has 3,322,832 subscription rights that have not yet been issued, indicating flexibility in future financing and potential enhancement of shareholder value.
See More
Nyxoah Secures $110 Million Financing to Accelerate U.S. Launch
- Significant Financing: Nyxoah has successfully completed a $95 million equity financing and anticipates receiving a $15 million second tranche from the European Investment Bank loan by the end of June 2026, totaling $110 million in new capital, which provides robust financial support for the company's expansion into the U.S. market.
- Commercialization Acceleration: This financing will expedite the commercialization of the Genio system in the U.S., where the company has established 40 sales representatives under an experienced commercial leadership team, aiming to enhance market penetration and meet the growing customer demand.
- Strategic Leadership Transition: CEO Olivier Taelman stated that this financing marks a defining moment for the company, enabling it to build on the strong momentum from its first two commercial quarters in the U.S. and further drive the market launch of Genio, thereby enhancing its competitiveness in the obstructive sleep apnea sector.
- Investor Confidence Boost: Chairman Robert Taub emphasized that the strong participation from both new and existing investors is a powerful endorsement of Genio technology and the company's strategy, securing a solid financial foundation that lays the groundwork for long-term value creation for shareholders.
See More
Nyxoah SA Reports 21% Revenue Growth in Q2 2026
- Significant Revenue Growth: Nyxoah SA reported preliminary revenue of approximately €7.7 million for Q2 2026, reflecting a 21% sequential increase over Q1 2026, indicating strong market performance and ongoing growth potential.
- Strong U.S. Market Performance: The company expects U.S. net revenue to be around €5.2 million, representing a 22% sequential growth from Q1 2026, demonstrating the effectiveness of its expansion strategy in the U.S. market and further solidifying its market position.
- Robust Financing Situation: Nyxoah secured $110 million in aggregate financing in Q2, enhancing its financial flexibility, with cash, cash equivalents, and financial assets expected to be approximately €97.8 million as of June 30, 2026, providing a solid foundation for future investments.
- Stable Annual Revenue Outlook: The company anticipates global net revenue for 2026 to be in the range of €36 million to €40 million, reflecting confidence in future market demand and a strategic plan for sustained growth.
See More
Nyxoah SA Voting Rights and Share Information Released
- Share Issuance: Nyxoah SA issued 146,531 new shares on June 30, 2026, increasing its total share capital to EUR 7,075,152.31, indicating a proactive approach to expanding its capital base.
- Total Voting Rights: The total number of voting rights currently stands at 100,072,815, all of which are ordinary shares, providing investors with transparent shareholder structure information that helps enhance market confidence.
- Unissued Subscription Rights: The company has 3,731,884 subscription rights that have not yet been issued, which presents potential opportunities for future financing and further expansion of shareholder equity.
- Convertible Bond Information: Nyxoah SA currently holds 225 convertible bonds with a nominal value of EUR 83,000 each, and if fully converted, would generate 12,618,243 new shares, further diluting the existing shareholders' equity.
See More
Nyxoah Receives Transparency Notifications from Major Shareholders
- Shareholder Notification: In accordance with Article 14 of the Law of May 2, 2007, Nyxoah SA received a transparency notification from Orin Hirchman, indicating that entities controlled by him held 14,534,880 voting rights as of June 10, 2026, representing 14.55% of total shares, highlighting his significant shareholder status in the company.
- Holding Structure Explanation: Hirchman controls these shares through AIGH Capital Management LLC, which manages two affiliated funds, AIGH Investment Partners, LP and WVP Emerging Manager Onshore Fund LLC, indicating his pivotal role in investment decisions that could influence the company's strategic direction.
- Resmed Inc. Notification: On the same day, Nyxoah also received a transparency notification from Resmed Inc., indicating a passive downward crossing to 1.95% voting rights as of June 10, 2026, reflecting a reduction in their stake that may affect market confidence in their holdings.
- Transparency Compliance: This notification complies with transparency regulations, ensuring a clear understanding of shareholder structure in the market, enhancing investor trust in corporate governance, and providing a transparent foundation for future capital operations.
See More
Nyxoah Invites Shareholders to Extraordinary Meeting on July 9, 2026
- Extraordinary Meeting Details: Nyxoah is set to hold its extraordinary shareholders' meeting on July 9, 2026, at 2:00 PM CET at its headquarters in Belgium, allowing shareholders to participate remotely via video conference, thereby enhancing shareholder engagement and interaction.
- Capital Authorization Renewal Proposal: The agenda includes a proposal from the board to renew the authorization for capital increases over the next five years, aimed at providing financial support for the company's long-term growth and enhancing capital flexibility.
- Voting and Participation Requirements: Shareholders must register by June 25, 2026, and notify the company of their intention to participate by July 3, ensuring compliance and increasing the effectiveness of voting, which promotes active shareholder involvement.
- Transparency and Data Protection: The company commits to adhering to its privacy policy while processing personal data during the shareholders' meeting, ensuring the security and transparency of shareholder information, which enhances trust in the company.
See More
Nyxoah Discloses Voting Rights and Share Information
- Share Issuance: Nyxoah SA issued 55,232,558 new shares in its underwritten public offering in the U.S., raising its total share capital to EUR 7,073,687, indicating active engagement in capital markets and financing capabilities.
- Total Voting Rights: As of June 10, 2026, Nyxoah has a total of 99,926,284 voting rights, all pertaining to ordinary shares, reflecting the company's transparency and compliance in shareholder structure.
- Convertible Bonds Information: The company currently has 225 convertible bonds with a nominal value of EUR 83,000 each, which could potentially convert into 12,618,243 voting rights, showcasing opportunities for capital expansion.
- Subscription Rights Status: As of May 31, 2026, Nyxoah has 3,322,832 subscription rights that have not yet been issued, indicating flexibility in future financing and potential enhancement of shareholder value.
See More
Nyxoah Secures $110 Million Financing to Accelerate U.S. Launch
- Significant Financing: Nyxoah has successfully completed a $95 million equity financing and anticipates receiving a $15 million second tranche from the European Investment Bank loan by the end of June 2026, totaling $110 million in new capital, which provides robust financial support for the company's expansion into the U.S. market.
- Commercialization Acceleration: This financing will expedite the commercialization of the Genio system in the U.S., where the company has established 40 sales representatives under an experienced commercial leadership team, aiming to enhance market penetration and meet the growing customer demand.
- Strategic Leadership Transition: CEO Olivier Taelman stated that this financing marks a defining moment for the company, enabling it to build on the strong momentum from its first two commercial quarters in the U.S. and further drive the market launch of Genio, thereby enhancing its competitiveness in the obstructive sleep apnea sector.
- Investor Confidence Boost: Chairman Robert Taub emphasized that the strong participation from both new and existing investors is a powerful endorsement of Genio technology and the company's strategy, securing a solid financial foundation that lays the groundwork for long-term value creation for shareholders.
See More
